Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GYNET trial of NP137 with carboplatin + paclitaxel and/or pembrolizumab in advanced endometrial or cervical cancer
2024-510714-32-00Phase 2Authorised
- Sponsor
- NETRIS Pharma
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of np137 in endometrial cancer (EC) and Cervical Cancer (CC) (2 arms), sponsored by NETRIS Pharma. Primary endpoint: Overall response rate after 3 months. Planned start Dec 2020; status: authorised.
02
Drugs
np137
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-510714-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510714-32-00.